Form 4: Bioventus Officer's Equity Grants & Vesting

Bioventus SVP & Chief Compliance Officer Katrina J. Church reported new equity grants and vesting of existing awards, alongside tax-related stock dispositions.

Summary

• Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc. (BVS), reported several transactions related to her equity holdings.
• On March 13, 2026, 3,455 Class A Common Stock shares were acquired upon the vesting of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, 1,501 Class A Common Stock shares were disposed of at $8.62 per share to cover tax withholding obligations related to the vesting.
• Additionally, 3,500 Class A Common Stock shares were acquired upon the vesting of other RSUs at a price of $0.
• Another 1,521 Class A Common Stock shares were disposed of at $8.62 per share for tax withholding purposes.
• Following these transactions, Ms. Church beneficially owns 61,732 Class A Common Stock shares directly.
• New derivative securities were granted: 14,000 Restricted Stock Units (RSUs) and 16,000 Stock Options (exercise price $9.61) on March 14, 2025.
• Further new derivative securities were granted: 24,000 Restricted Stock Units (RSUs) and 27,000 Stock Options (exercise price $8.62) on March 13, 2026.
• The RSUs and options granted on March 14, 2025, will vest in four equal annual installments starting March 15, 2025.
• The RSUs and options granted on March 13, 2026, will vest in four equal annual installments starting March 15, 2026.
• The stock options granted on March 14, 2025, expire on March 14, 2035, and those granted on March 13, 2026, expire on March 13, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as new equity grants align management's long-term interests with shareholders, indicating continued commitment to the company. The dispositions are routine for tax purposes.

Positives

• The SVP & Chief Compliance Officer received new grants of 38,000 Restricted Stock Units and 43,000 Stock Options, aligning her interests with long-term shareholder value.
• Existing Restricted Stock Units vested, resulting in the acquisition of 6,955 shares of Class A Common Stock, demonstrating the realization of prior equity compensation.

Negatives

• A total of 3,022 Class A Common Stock shares were disposed of at $8.62 per share to cover tax withholding obligations, reducing direct beneficial ownership.

Future Outlook

The reporting person's future equity compensation is structured with multi-year vesting schedules for both Restricted Stock Units and Stock Options, extending through March 2029 and March 2030 respectively, contingent on continued service.

Industry Context

StockSavvy.ai notes this is a routine insider transaction filing, common across all industries, reflecting standard executive compensation practices involving equity grants and the subsequent handling of tax obligations upon vesting. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The new equity grants to a key executive align management's incentives with shareholder value creation over the long term.
• Employees: Reflects standard executive compensation practices, which can influence broader employee compensation strategies.

Next Steps

• Continued vesting of 14,000 RSUs and 16,000 Stock Options in four equal annual installments starting March 15, 2025.
• Continued vesting of 24,000 RSUs and 27,000 Stock Options in four equal annual installments starting March 15, 2026.
• Potential exercise of Stock Options granted on March 14, 2025, until their expiration on March 14, 2035.
• Potential exercise of Stock Options granted on March 13, 2026, until their expiration on March 13, 2036.

Key Dates

Keywords

Bioventus, BVS, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Officer Holdings, Vesting, Tax Withholding